Bill's Feed
Nov 20, 2013

Smokers who quit may cut heart risk faster than had been thought

DALLAS, Nov 20 (Reuters) – Some cigarette smokers over 65
years old who kick the habit may be able to reduce their risk of
dying from heart-related problems to the level of those who
never smoked far faster than previously believed, according to
new research presented on Wednesday.

Previous research found that older former smokers who had
consumed less than 32 pack years of cigarettes could reduce
their risk of dying from heart disease to the level of lifelong
nonsmokers after 15 years.

Nov 20, 2013

New Daiichi drug succeeds in major study; set to face rivals

DALLAS (Reuters) – A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market.

The drug, edoxaban, met the main efficacy and safety goals of the study by demonstrating “non-inferiority” to warfarin in preventing strokes and blood clots and led to significantly less major bleeding – the greatest danger of blood thinning medicines.

Nov 19, 2013

Signs of ‘sudden’ cardiac death may come weeks before -study

Nov 18 (Reuters) – Signs of approaching “sudden” cardiac
arrest, an electrical malfunction that stops the heart, usually
appear at least a month ahead of time, according to a study of
middle-age men in Portland, Oregon.

“We’re looking at how to identify the Tim Russerts and Jim
Gandolfinis – middle aged men in their 50s who drop dead and we
don’t have enough information why,” said Sumeet Chugh, senior
author of the study and associate director for genomic
cardiology at the Cedars-Sinai Heart Institute in Los Angeles.

Nov 19, 2013

Amgen cholesterol drug appears safe, cut LDL 52 percent at 1 year: study

DALLAS (Reuters) – Amgen Inc’s experimental heart medicine from a closely watched new class of drugs called PCSK9 inhibitors lowered “bad” LDL cholesterol 52 percent after one year with no major increase in serious adverse side effects compared with standard drugs, such as statins, according to data from a study.

The clinical trial of the drug, evolocumab, marks the first data looking at 52 weeks of use for the new class of injectable biotech medicines seen as potentially the biggest advance in the field of cholesterol therapy in many years.

Nov 19, 2013

Signs of ‘sudden’ cardiac death may come weeks before -study

Nov 18 (Reuters) – Signs of approaching “sudden” cardiac
arrest, an electrical malfunction that stops the heart, usually
appear at least a month ahead of time, according to a study of
middle-age men in Portland, Oregon.

“We’re looking at how to identify the Tim Russerts and Jim
Gandolfinis – middle aged men in their 50s who drop dead and we
don’t have enough information why,” said Sumeet Chugh, senior
author of the study and associate director for genomic
cardiology at the Cedars-Sinai Heart Institute in Los Angeles.

Nov 19, 2013

Amgen cholesterol drug appears safe, cut LDL 52 pct at 1 year-study

DALLAS, Nov 19 (Reuters) – Amgen Inc’s experimental
heart medicine from a closely watched new class of drugs called
PCSK9 inhibitors lowered “bad” LDL cholesterol 52 percent after
one year with no major increase in serious adverse side effects
compared with standard drugs, such as statins, according to data
from a study.

The clinical trial of the drug, evolocumab, marks the first
data looking at 52 weeks of use for the new class of injectable
biotech medicines seen as potentially the biggest advance in the
field of cholesterol therapy in many years.

Nov 19, 2013

Gene analysis fails to help predict best warfarin dose

By Ransdell Pierson and Bill Berkrot

(Reuters) – Gene analysis failed in a U.S. clinical trial to help doctors select better doses of warfarin, the widely used blood-thinner, which can cause dangerous bleeding if doses are too high and fail to protect against blood clots and strokes if doses are too low.

Warfarin, an oral drug that has been on the market for more than 60 years, is used to prevent strokes in people with an irregular heartbeat called atrial fibrillation and to prevent dangerous blood clots in veins and in the lungs.

Nov 19, 2013

Daiichi blood thinner safer, as effective as warfarin -study

DALLAS, Nov 19 (Reuters) – A new blood clot and stroke
preventer from Daiichi Sankyo proved as effective and
safer than widely used warfarin in a large, late stage trial of
patients with atrial fibrillation, paving the way for it to
compete with other new warfarin alternatives on the market.

The drug, edoxaban, met the main efficacy and safety goals
of the study by demonstrating “non-inferiority” to warfarin in
preventing strokes and blood clots and led to significantly less
major bleeding – the greatest danger of blood thinning
medicines.

Nov 19, 2013

Daiichi blood thinner safer, as effective as warfarin in major study

DALLAS (Reuters) – A new blood clot and stroke preventer from Daiichi Sankyo proved as effective and safer than widely used warfarin in a large, late stage trial of patients with atrial fibrillation, paving the way for it to compete with other new warfarin alternatives on the market.

The drug, edoxaban, met the main efficacy and safety goals of the study by demonstrating “non-inferiority” to warfarin in preventing strokes and blood clots and led to significantly less major bleeding – the greatest danger of blood thinning medicines.

Nov 18, 2013

Heart guidelines authors defend method of calculating risk

Dallas (Reuters) – Top cardiologists who devised new U.S. guidelines for reducing risk of heart disease strenuously defended their risk-calculation tool from criticism that it greatly overestimates health risks and the need to be treated with statins.

Two Harvard professors, Dr. Paul Ridker and Dr. Nancy Cook, sparked the controversy by saying the guidelines overestimate risk of developing heart disease up to 150 percent for some populations, according to a report in Monday’s New York Times. The report said their criticisms would appear Tuesday in the British medical journal The Lancet.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill